BR0209564A - Animal transgênico, embrião, camundongo transgênico, modelo animal para o estudo da modulação da densidade óssea, célula isolada, ácido nucleico para marcar o gene pela recombinação homóloga, e, métodos para estudar determinantes da massa óssea, para estudar moduladores de massa óssea, para estudar a massa óssea, para estudar um efeito hbm sobre os distúrbios ósseos, para identificar marcadores substitutos da formação/reabsorção ósseas, para estudar efeitos de hbm sobre os distúrbios cardìacos, para avaliar tratamentos cárdio-protetores quanto aos efeitos de modulação da massa óssea, para modular a densidade óssea, para produzir um camundongo transgênico e para identificar genes associados com a massa óssea - Google Patents
Animal transgênico, embrião, camundongo transgênico, modelo animal para o estudo da modulação da densidade óssea, célula isolada, ácido nucleico para marcar o gene pela recombinação homóloga, e, métodos para estudar determinantes da massa óssea, para estudar moduladores de massa óssea, para estudar a massa óssea, para estudar um efeito hbm sobre os distúrbios ósseos, para identificar marcadores substitutos da formação/reabsorção ósseas, para estudar efeitos de hbm sobre os distúrbios cardìacos, para avaliar tratamentos cárdio-protetores quanto aos efeitos de modulação da massa óssea, para modular a densidade óssea, para produzir um camundongo transgênico e para identificar genes associados com a massa ósseaInfo
- Publication number
- BR0209564A BR0209564A BR0209564-5A BR0209564A BR0209564A BR 0209564 A BR0209564 A BR 0209564A BR 0209564 A BR0209564 A BR 0209564A BR 0209564 A BR0209564 A BR 0209564A
- Authority
- BR
- Brazil
- Prior art keywords
- study
- bone
- bone mass
- hbm
- mass
- Prior art date
Links
- 210000000988 bone and bone Anatomy 0.000 title abstract 9
- 238000000034 method Methods 0.000 title abstract 7
- 108090000623 proteins and genes Proteins 0.000 title abstract 7
- 241001465754 Metazoa Species 0.000 title abstract 4
- 230000037182 bone density Effects 0.000 title abstract 4
- 230000000694 effects Effects 0.000 title abstract 4
- 230000009261 transgenic effect Effects 0.000 title abstract 4
- 238000011830 transgenic mouse model Methods 0.000 title abstract 4
- 108020004707 nucleic acids Proteins 0.000 title abstract 3
- 102000039446 nucleic acids Human genes 0.000 title abstract 3
- 150000007523 nucleic acids Chemical class 0.000 title abstract 3
- 238000010171 animal model Methods 0.000 title abstract 2
- 230000004821 effect on bone Effects 0.000 title abstract 2
- 210000001161 mammalian embryo Anatomy 0.000 title abstract 2
- 208000020084 Bone disease Diseases 0.000 title 1
- 208000020446 Cardiac disease Diseases 0.000 title 1
- 230000024279 bone resorption Effects 0.000 title 1
- 230000003293 cardioprotective effect Effects 0.000 title 1
- 208000019622 heart disease Diseases 0.000 title 1
- 238000002744 homologous recombination Methods 0.000 title 1
- 230000006801 homologous recombination Effects 0.000 title 1
- 230000011164 ossification Effects 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
- 230000014461 bone development Effects 0.000 abstract 2
- 239000003155 DNA primer Substances 0.000 abstract 1
- 241000699660 Mus musculus Species 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 abstract 1
- 210000004102 animal cell Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000010367 cloning Methods 0.000 abstract 1
- -1 coding sequences Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000002751 oligonucleotide probe Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000006798 recombination Effects 0.000 abstract 1
- 238000005215 recombination Methods 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/50—Amphibians, e.g. Xenopus
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/02—Animal zootechnically ameliorated
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/60—Vectors containing traps for, e.g. exons, promoters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
- C12N2840/105—Vectors comprising a special translation-regulating system regulates levels of translation enhancing translation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Environmental Sciences (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Biodiversity & Conservation Biology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Husbandry (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
"ANIMAL TRANSGêNICO, EMBRIãO, CAMUNDONGO TRANSGêNICO, MODELO ANIMAL PARA O ESTUDO DA MODULAçãO DA DENSIDADE óSSEA, CéLULA ISOLADA , áCIDO NUCLEICO PARA MARCAR O GENE PELA RECOMBINAçãO HOMóLOGA, E, MéTODOS PARA ESTUDAR DETERMINANTES DA MASSA óSSEA, PARA ESTUDAR MODULADORES DE MASSA óSSEA, PARA ESTUDAR A MASSA óSSEA, PARA ESTUDAR UM EFEITO DE HBM SOBRE OS DISTúRBIOS óSSEOS, PARA IDENTIFICAR MARCADORES SUBSTITUTOS DA FORMAçãO/REABSORçãO óSSEAS, PARA ESTUDAR EFEITOS DE HBM SOBRE OS DISTúRBIOS CARDìACOS, PARA AVALIAR TRATAMENTOS CáRDIO-PROTETORES QUANTO AOS EFEITOS DE MODULAçãO DA MASSA óSSEA, PARA MODULAR A DENSIDADE óSSEA, PARA PRODUZIR UM CAMUNDONGO TRANSGêNICO E PARA IDENTIFICAR GENES ASSOCIADOS COM A MASSA óSSEA". A presente invenção diz respeito a métodos e materiais usados para expressar a proteina HBM em células de animal e animais transgênicos. A presente invenção também diz respeito aos animais transgênicos que expressam o gene da massa óssea alta, o gene do tipo selvagem correspondente e mutantes destes. A invenção fornece ácidos nucleicos, incluindo seq³ências codificadoras, iniciadores de oligonucleotídeo e sondas, proteinas, vetores de clonagem, vetores de expressão, hospedeiros transformados, métodos de desenvolver composições farmacêuticas, métodos de identificar moléculas envolvidas no desenvolvimento ósseo e métodos de diagnosticar e tratar doenças envolvidas no desenvolvimento ósseo. Em formas de realização preferidas, a presente invenção está direcionada a métodos para tratar, diagnosticar e prevenir a osteoporose.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29007101P | 2001-05-11 | 2001-05-11 | |
US29131101P | 2001-05-17 | 2001-05-17 | |
US35305802P | 2002-02-01 | 2002-02-01 | |
US36129302P | 2002-03-04 | 2002-03-04 | |
PCT/US2002/014876 WO2002092764A2 (en) | 2001-05-11 | 2002-05-13 | Transgenic animal model of bone mass modulation |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0209564A true BR0209564A (pt) | 2004-10-26 |
Family
ID=27501520
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0209563-7A BR0209563A (pt) | 2001-05-11 | 2002-05-13 | ácido nucleico, polipeptìdeo, vetor, célula, anticorpo, métodos de diagnosticar um fenótipo e um paciente como expressando um ácido nucleico e de identificar agentes que modulam a atividade de um ácido nucleico e de uma proteìna e lrp5, lrp6, ou hbm e compostos que modulam a interação de dkk com o caminho de sinalização wnt, composição para modular a massa óssea e/ou os nìveis de lipìdeo em um paciente, animal transgênico, embrião e modelo de animal, e, agente |
BR0209564-5A BR0209564A (pt) | 2001-05-11 | 2002-05-13 | Animal transgênico, embrião, camundongo transgênico, modelo animal para o estudo da modulação da densidade óssea, célula isolada, ácido nucleico para marcar o gene pela recombinação homóloga, e, métodos para estudar determinantes da massa óssea, para estudar moduladores de massa óssea, para estudar a massa óssea, para estudar um efeito hbm sobre os distúrbios ósseos, para identificar marcadores substitutos da formação/reabsorção ósseas, para estudar efeitos de hbm sobre os distúrbios cardìacos, para avaliar tratamentos cárdio-protetores quanto aos efeitos de modulação da massa óssea, para modular a densidade óssea, para produzir um camundongo transgênico e para identificar genes associados com a massa óssea |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0209563-7A BR0209563A (pt) | 2001-05-11 | 2002-05-13 | ácido nucleico, polipeptìdeo, vetor, célula, anticorpo, métodos de diagnosticar um fenótipo e um paciente como expressando um ácido nucleico e de identificar agentes que modulam a atividade de um ácido nucleico e de uma proteìna e lrp5, lrp6, ou hbm e compostos que modulam a interação de dkk com o caminho de sinalização wnt, composição para modular a massa óssea e/ou os nìveis de lipìdeo em um paciente, animal transgênico, embrião e modelo de animal, e, agente |
Country Status (7)
Country | Link |
---|---|
US (2) | US7416849B2 (pt) |
EP (2) | EP1401269A4 (pt) |
JP (3) | JP2004537289A (pt) |
AU (2) | AU2002316095A1 (pt) |
BR (2) | BR0209563A (pt) |
CA (2) | CA2446859A1 (pt) |
WO (2) | WO2002092764A2 (pt) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6770461B1 (en) | 1998-10-23 | 2004-08-03 | Genome Therapeutics Corporation | High bone mass gene of 11q13.3 |
US6780609B1 (en) * | 1998-10-23 | 2004-08-24 | Genome Therapeutics Corporation | High bone mass gene of 1.1q13.3 |
WO2001092891A2 (en) * | 2000-05-26 | 2001-12-06 | Genome Therapeutics Corporation | Regulating lipid levels via the zmax1 or hbm gene |
CA2446859A1 (en) | 2001-05-11 | 2002-11-21 | Wyeth | Transgenic animal model of bone mass modulation |
US7514594B2 (en) * | 2001-05-11 | 2009-04-07 | Wyeth | Transgenic animal model of bone mass modulation |
US20040038860A1 (en) | 2002-05-17 | 2004-02-26 | Allen Kristina M. | Reagents and methods for modulating dkk-mediated interactions |
CA2446582A1 (en) * | 2001-05-17 | 2002-11-21 | Genome Therapeutics Corporation | Reagents and methods for modulating dkk-mediated interactions |
US9453251B2 (en) | 2002-10-08 | 2016-09-27 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
CA2515081A1 (en) | 2003-02-07 | 2004-08-19 | Protein Design Labs, Inc. | Amphiregulin antibodies and their use to treat cancer and psoriasis |
FR2856410B1 (fr) * | 2003-06-20 | 2007-06-15 | Integragen Sa | Methodes de preparation de puces genetiques et utilisations |
WO2005048913A2 (en) * | 2003-11-24 | 2005-06-02 | Gunnar Westin | Mutant lrp5/6 wnt-signaling receptors in cancer diagnosis, prognosis and treatment |
ES2427177T3 (es) * | 2004-04-27 | 2013-10-29 | Galapagos N.V. | Métodos, agentes y ensayos de detección de compuestos para inducir diferenciación de células de mamífero no diferenciadas para dar lugar a osteoblastos |
EP2423326B1 (en) * | 2004-05-07 | 2014-01-08 | Celera Corporation | Genetic polymorphism associated with liver fibrosis methods of detection and uses thereof |
CN101031655A (zh) | 2004-07-26 | 2007-09-05 | 陶氏环球技术公司 | 通过株工程改进蛋白表达的方法 |
EP2336177A1 (en) * | 2004-08-04 | 2011-06-22 | Amgen, Inc | Antibodies to DKK-1 |
US7771937B2 (en) * | 2005-05-20 | 2010-08-10 | University Of Washington | Methods for predicting late onset Alzheimer disease in an individual |
US20080293053A1 (en) * | 2006-12-28 | 2008-11-27 | The Regents Of The University Of Michigan | shRNA Materials and Methods of Using Same for Inhibition of DKK-1 |
HUE060822T2 (hu) | 2006-12-29 | 2023-04-28 | Ossifi Mab Llc | Módszerek a csontnövekedés megváltoztatására SOST vagy WISE antagonista vagy agonista adásával |
US9580719B2 (en) | 2007-04-27 | 2017-02-28 | Pfenex, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
WO2008134461A2 (en) | 2007-04-27 | 2008-11-06 | Dow Global Technologies, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
DK2567709T3 (en) | 2007-11-02 | 2018-03-12 | Novartis Ag | Molecules and Methods for Modulating Low-Density Lipoprotein Receptor-Related Protein 6 (LRP6) |
US8716243B2 (en) * | 2008-05-28 | 2014-05-06 | St. Jude Childen's Research Hospital | Methods of effecting Wnt signaling through Dkk structural analysis |
EP2286240B1 (en) * | 2008-06-03 | 2016-01-06 | Université de Liège | Biomarker for osteoarthritis and use thereof |
US20110197290A1 (en) | 2010-02-11 | 2011-08-11 | Fahrenkrug Scott C | Methods and materials for producing transgenic artiodactyls |
AU2011232514A1 (en) | 2010-03-24 | 2012-08-30 | Genentech, Inc. | Anti-LRP6 antibodies |
US9428583B2 (en) | 2010-05-06 | 2016-08-30 | Novartis Ag | Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies |
BR112012028326A2 (pt) | 2010-05-06 | 2017-03-21 | Novartis Ag | anticorpo multivalente isolado, anticorpos biparatópicos isolados, ácido nucleico, vetor, composição farmacêutica, método de obtenção dos referidos anticorpos, bem como uso do dos mesmos |
US10920242B2 (en) | 2011-02-25 | 2021-02-16 | Recombinetics, Inc. | Non-meiotic allele introgression |
TW201323442A (zh) | 2011-11-04 | 2013-06-16 | Novartis Ag | 低密度脂蛋白相關蛋白6(lrp6)-半衰期延長構築體 |
EP2858486A4 (en) * | 2012-06-12 | 2016-04-13 | Hoffmann La Roche | METHODS AND COMPOSITIONS FOR GENERATING ALLLETS WITH CONDITIONAL INACTIVATION |
US8959241B2 (en) * | 2012-07-23 | 2015-02-17 | Adobe Systems Incorporated | Method and apparatus for performing server-side splicing for live streaming media |
WO2015073922A2 (en) | 2013-11-15 | 2015-05-21 | Northwestern University | Inhibition of oxidative stress in atrial fibrillation |
WO2015089074A1 (en) | 2013-12-09 | 2015-06-18 | Baylor College Of Medicine | Hippo and dystrophin complex signaling in cardiomyocyte renewal |
TW201710503A (zh) | 2015-06-12 | 2017-03-16 | 長庚醫療財團法人林口長庚紀念醫院 | 新穎多核苷酸、載體、醫藥組成物以及其用途 |
US20180037909A1 (en) | 2016-08-04 | 2018-02-08 | Chang Gung Memorial Hospital, Linkou | Modified cancer cell lines and uses thereof |
US20190218306A1 (en) * | 2018-01-18 | 2019-07-18 | Nalini M. Rajamannan | Method of inhibiting ectopic calcification |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5283173A (en) * | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
WO1997012903A1 (en) | 1995-10-04 | 1997-04-10 | Warner-Lambert Company | Compounds, compositions and methods for inhibiting the binding of proteins containing an sh2 domain to cognate phosphorylated proteins |
US5691153A (en) * | 1996-09-06 | 1997-11-25 | Creighton University | Genetic markers to detect high bone mass |
US6555654B1 (en) * | 1997-04-15 | 2003-04-29 | The Wellcome Trust Limited As Trustee For The Wellcome Trust | LDL-receptor |
CA2286313C (en) * | 1997-04-15 | 2011-01-11 | The Wellcome Trust Limited As Trustee To The Wellcome Trust | Novel ldl-receptor |
BE1011331A6 (fr) | 1997-08-20 | 1999-07-06 | Univ Catholique De Louvain Hal | Polypeptide associe au peroxysome, sequence nucleotidique encodant ledit polypeptide et leur utilisation dans le diagnostic et/ou le traitement de maladies ou de lesions pulmonaires. |
JP2002506873A (ja) | 1998-03-18 | 2002-03-05 | アリアド・ファーマシューティカルズ・インコーポレイテッド | 複素環式シグナル伝達阻害剤、それを含む組成物 |
CA2370441A1 (en) | 1999-03-26 | 2000-10-05 | Craig A. Rosen | 50 human secreted proteins |
NZ521769A (en) * | 2000-04-05 | 2004-12-24 | Genome Therapeutics Corp | The high bone mass gene of 11q13.3 |
WO2001092891A2 (en) | 2000-05-26 | 2001-12-06 | Genome Therapeutics Corporation | Regulating lipid levels via the zmax1 or hbm gene |
CA2411978A1 (en) * | 2000-06-21 | 2001-12-27 | Deltagen, Inc. | Transgenic mice containing targeted gene disruptions |
EP1313753A4 (en) | 2000-08-18 | 2004-09-15 | Proskelia | REGULATOR GENES AND USEABLE SYSTEM FOR THE DIAGNOSIS AND THERAPY OF THE OSTEOPOROSIS |
CA2446859A1 (en) | 2001-05-11 | 2002-11-21 | Wyeth | Transgenic animal model of bone mass modulation |
US8637506B2 (en) * | 2003-09-22 | 2014-01-28 | Enzo Biochem, Inc. | Compositions and methods for bone formation and remodeling |
DE102007020878B4 (de) | 2007-05-04 | 2020-06-18 | Dr. Ing. H.C. F. Porsche Aktiengesellschaft | Verfahren zur Prüfung von Umströmungsgeräuschen |
-
2002
- 2002-05-13 CA CA002446859A patent/CA2446859A1/en not_active Abandoned
- 2002-05-13 EP EP02769713A patent/EP1401269A4/en not_active Withdrawn
- 2002-05-13 WO PCT/US2002/014876 patent/WO2002092764A2/en not_active Application Discontinuation
- 2002-05-13 JP JP2002588919A patent/JP2004537289A/ja not_active Withdrawn
- 2002-05-13 AU AU2002316095A patent/AU2002316095A1/en not_active Abandoned
- 2002-05-13 BR BR0209563-7A patent/BR0209563A/pt not_active Application Discontinuation
- 2002-05-13 EP EP02746370A patent/EP1483288A4/en not_active Withdrawn
- 2002-05-13 AU AU2002308681A patent/AU2002308681A1/en not_active Abandoned
- 2002-05-13 WO PCT/US2002/014877 patent/WO2002092000A2/en active Application Filing
- 2002-05-13 CA CA002446821A patent/CA2446821A1/en not_active Abandoned
- 2002-05-13 US US10/477,173 patent/US7416849B2/en not_active Expired - Fee Related
- 2002-05-13 JP JP2002589632A patent/JP2005511002A/ja not_active Withdrawn
- 2002-05-13 BR BR0209564-5A patent/BR0209564A/pt not_active Application Discontinuation
-
2008
- 2008-07-18 US US12/219,294 patent/US20090136507A1/en not_active Abandoned
-
2010
- 2010-06-28 JP JP2010146427A patent/JP2011004744A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US7416849B2 (en) | 2008-08-26 |
JP2004537289A (ja) | 2004-12-16 |
AU2002308681A1 (en) | 2002-11-25 |
WO2002092000A2 (en) | 2002-11-21 |
EP1483288A2 (en) | 2004-12-08 |
JP2005511002A (ja) | 2005-04-28 |
WO2002092764A2 (en) | 2002-11-21 |
EP1483288A4 (en) | 2005-09-21 |
BR0209563A (pt) | 2004-12-07 |
WO2002092764A3 (en) | 2003-12-24 |
CA2446859A1 (en) | 2002-11-21 |
EP1401269A4 (en) | 2005-09-28 |
AU2002316095A1 (en) | 2002-11-25 |
US20090136507A1 (en) | 2009-05-28 |
WO2002092000A3 (en) | 2004-10-07 |
EP1401269A2 (en) | 2004-03-31 |
US20050070699A1 (en) | 2005-03-31 |
JP2011004744A (ja) | 2011-01-13 |
CA2446821A1 (en) | 2002-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0209564A (pt) | Animal transgênico, embrião, camundongo transgênico, modelo animal para o estudo da modulação da densidade óssea, célula isolada, ácido nucleico para marcar o gene pela recombinação homóloga, e, métodos para estudar determinantes da massa óssea, para estudar moduladores de massa óssea, para estudar a massa óssea, para estudar um efeito hbm sobre os distúrbios ósseos, para identificar marcadores substitutos da formação/reabsorção ósseas, para estudar efeitos de hbm sobre os distúrbios cardìacos, para avaliar tratamentos cárdio-protetores quanto aos efeitos de modulação da massa óssea, para modular a densidade óssea, para produzir um camundongo transgênico e para identificar genes associados com a massa óssea | |
Joyner et al. | Genetic inducible fate mapping in mouse: establishing genetic lineages and defining genetic neuroanatomy in the nervous system | |
MXPA03010077A (es) | Abonadora de siembra a voleo con deflector movible. | |
Burke et al. | Hox genes and the evolution of vertebrate axial morphology | |
Im et al. | Pokes, sunburn, and hot sauce: Drosophila as an emerging model for the biology of nociception | |
Kornberg et al. | The engrailed locus of Drosophila: in situ localization of transcripts reveals compartment-specific expression | |
Byrne et al. | Neural models of plasticity: Experimental and theoretical approaches | |
Wolpert | Positional information and pattern formation | |
Fetcho et al. | Some principles of organization of spinal neurons underlying locomotion in zebrafish and their implications | |
Gottesman et al. | Tumor promoters and Kirsten sarcoma virus increase synthesis of a secreted glycoprotein by regulating levels of translatable mRNA | |
Bernstein et al. | Fine tuning a molecular motor: the location of alternative domains in the Drosophila myosin head | |
Teng et al. | Resolving homology in the face of shifting germ layer origins: Lessons from a major skull vault boundary | |
Ellwanger et al. | GABA and glutamate specifically induce contractions in the sponge Tethya wilhelma | |
DE69830065D1 (de) | Methoden zur kompletten chemischen synthese und zusammensetzung von genen und genomen | |
Djurdjevič et al. | Comparative transcriptome analysis of trout skin pigment cells | |
Hanken et al. | Evolution of cranial development and the role of neural crest: insights from amphibians | |
Birinyi et al. | Synaptic targets of commissural interneurons in the lumbar spinal cord of neonatal rats | |
Olivo et al. | Brain sensory organs of the Ascidian Ciona robusta: Structure, function and developmental mechanisms | |
ATE440967T1 (de) | Auswahl von tieren für gewünschte genotypische und potentielle phänotypische eigenschaften auf der basis eines einzelnen nukleotidpolymorphismus (snp) im intron 3 des igf2-gens | |
Qi et al. | A DRG genetic toolkit reveals molecular, morphological, and functional diversity of somatosensory neuron subtypes | |
BR0017197A (pt) | Sequência de ácido nucleico, sequência de aminoácido, vetor de clonagem replicativo, célula hospedeira isolada vetor de expressão, métodos para testar uma substância como um agente terapêutico para modulação óssea em um hospedeiro, para identificar uma molécula e uma proteìna candidata envolvidas na modulação óssea, para testar quanto a atividade de hbm, para desenvolvimento farmacêutico para o tratamento de distúrbios do desenvolvimento ósseo, para tratar um distúrbio do desenvolvimento ósseo em um animal, para alterar o desenvolvimento ósseo em um hospedeiro, para tratar a osteoporose, para avaliar diagnóstico para uma predisposição genética a um distúrbio do desenvolvimento ósseo, para identificar uma predisposição genética para distúrbios do desenvolvimento ósseo, para expressar a proteìna de hbm em tecido ósseo, para amplificar um polimorfismo de nucleotìdeo, para identificar um elemento regulador de um gene de hbm e para modular densidade óssea em um paciente, ensaio de diagnóstico para distúrbios do desenvolvimento ósseo, cromossoma artificial bacteriano, segmento de ácido nucleico isolado, ácido nucleico, e, polipeptìdeo. | |
Kavanagh | Developmental plasticity associated with early structural integration and evolutionary patterns: Examples of developmental bias and developmental facilitation in the skeletal system | |
Demeneix et al. | Gene transfer into intact vertebrate embryos | |
Benninger et al. | Transitional nerve: a new and original classification of a peripheral nerve supported by the nature of the accessory nerve (CN XI) | |
Sharp | Sensory regulation of spontaneous limb movements in the midstage embryonic chick |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired |